• 1.

    Prata A , 2001. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 1 : 92100.

  • 2.

    Rassi A Jr , Rassi A , Marin-Neto , 2010. Chagas disease. Lancet 375 : 13881402.

  • 3.

    Koberle F , 1970. The causation and importance of nervous lesions in American trypanosomiasis. Bull World Health Organ 42 : 739743.

  • 4.

    Dias JCP , 1995. Natural history of Chagas’ disease. Arq Bras Cardiol 65 : 359366.

  • 5.

    Rassi A , Rezende JM , Luquetti AO , Rassi A Jr , 2017. Clinical phases and forms of Chagas disease. Telleria J , Tibayrenc M , eds. American Trypanosomiasis. Chagas Disease. One Hundred Years of Research, 2nd edition. Amsterdam, The Netherlands: Elsevier, 653686.

    • Search Google Scholar
    • Export Citation
  • 6.

    Rezende JM , Luquetti AO , 1994. Chagasic megavisceras. Pan American Health Organization, eds. Chagas’ disease and the Nervous System. Washington, DC: Scientific Publication No. 547, 149171.

    • Search Google Scholar
    • Export Citation
  • 7.

    Gomes YM , Lorena VMB , Luquetti AO , 2009. Diagnosis of Chagas disease: what has been achieved? What remains to be done with regard to diagnosis and follow up studies? Mem Inst Oswaldo Cruz 104 (Supp I):115121.

    • Search Google Scholar
    • Export Citation
  • 8.

    Cossio PM , Laghens RP , Diez C , Szarfman A , Segal A , Arana RM , 1974. Chagasic cardiopathy: antibodies reacting with plasma membrane of striated muscle and endothelial cells. Circulation 50 : 12521259.

    • Search Google Scholar
    • Export Citation
  • 9.

    Szarfman A , Luquetti A , Rassi A , Rezende JM , Schmunis GA , 1981. Tissue-reacting immunoglobulins in patients with different clinical forms of Chagas’ disease. Am J Trop Med Hyg 30 : 4346.

    • Search Google Scholar
    • Export Citation
  • 10.

    Scharfstein J , Luquetti A , Murta ACM , Senna M , Rezende JM , Rassi A , Mendonça-Previato L , 1985. Chagas’ disease: serodiagnosis with purified Gp25 antigen. Am J Trop Med Hyg 34 : 11531160.

    • Search Google Scholar
    • Export Citation
  • 11.

    Schechter M , Luquetti AO , Rezende JM , Rassi A , Miles MA , 1985. Further evaluation of lectin affinity purified glycoprotein (GP90) in the enzyme linked immunosorbent assay (ELISA) for diagnosis of Trypanosoma cruzi infection. Trans R Soc Trop Med Hyg 79 : 637640.

    • Search Google Scholar
    • Export Citation
  • 12.

    Shaw MA , 2017. Human genetic susceptibility to Chagas disease. Telleria J , Tibayrenc M , eds. American Trypanosomiasis. Chagas Disease. One Hundred Years of Research, 2nd edition. Amsterdam, The Netherlands: Elsevier, 629652.

    • Search Google Scholar
    • Export Citation
  • 13.

    Argüeso P , Panjwani N , 2011. Focus on molecules: Galectin-3. Exp Eye Res 92 : 23.

  • 14.

    Newlaczyl AU , Yu LG , 2011. Galectin-3-a jack-of-all-trades in cancer. Cancer Lett 313 : 123128.

  • 15.

    Dong R , Zhang M , Hu Q , Zheng S , Soh A , Zheng Y , Yuan H , 2018. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Int J Mol Med 41 : 599614.

    • Search Google Scholar
    • Export Citation
  • 16.

    Lopez-Andrès N , Rossignol P , Iraqi W , Fay R , Nuée J , Ghio S , Cleland JG , Zannad F , Lacolley P , 2012. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 14 : 7481.

    • Search Google Scholar
    • Export Citation
  • 17.

    Daniels LB , Maisel AS , 2007. Natriuretic peptides. J Am Coll Cardiol 50 : 23572368.

  • 18.

    Liu XY , Huang YT , Lai MY , Chen J , Chu TW , Tsay PK , Shiao CC , 2018. Predicting cardiogenic pulmonary edema in heart failure patients by using an N-terminal pro-b-type natriuretic peptide (NT-pro BNP)-based score. Clin Chim Acta 480 : 2633.

    • Search Google Scholar
    • Export Citation
  • 19.

    Esther N et al., 2017. NT-proBNP is increased in differentiated thyroid carcinoma patients and may predict cardiovascular risk. Clin Biochem 50 : 696702.

    • Search Google Scholar
    • Export Citation
  • 20.

    Sherbuk JE et al., 2015. Biomarkers and mortality in severe Chagas cardiomyopathy. Glob Heart 10 : 173180.

  • 21.

    Yichuan F , Zhao X , Li X , Li N , Hu N , 2018. Cardiac troponin and adverse outcomes. Clin Chim Acta 477 : 4852.

  • 22.

    Drakopanagiotakis F , Wujak L , Wygrecka M , Markart P , 2018. Biomarkers in idiopathic pulmonary fibrosis. Matrix Biol. https://doi.org/10.1016/j.matbio.2018.01.023.

    • Search Google Scholar
    • Export Citation
  • 23.

    Kuschnir E , Sgammini H , Castro R , Evequoz C , Ledesma R , Brunetto J , 1985. Valoración de la función cardíaca por angiografía radioisotópica en pacientes con cardiopatía chagásica crónica. Arq Bras Cardiol 45 : 249256.

    • Search Google Scholar
    • Export Citation
  • 24.

    Luquetti AO , Miles MA , Rassi A , de Rezende JM , de Souza AA , Povoa MM , Rodrigues I , 1986. Trypanosoma cruzi: zymodemes associated with acute and chronic Chagas’ disease in central Brazil. Trans R Soc Trop Med Hyg 80 : 462470.

    • Search Google Scholar
    • Export Citation
  • 25.

    Dias JCP et al., 2016. II Consenso Brasileiro em Doença de Chagas, 2015. Rev Epidemiol Serv Saúde 25 (num.esp.): 7–86.

Past two years Past Year Past 30 Days
Abstract Views 2442 2442 113
Full Text Views 50 50 7
PDF Downloads 85 85 7
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 

 

Evaluation of Four Biomarkers in Patients Chronically Infected with Trypanosoma cruzi and Their Relationship with Disease Progression

Dayse Elisabeth Campos de OliveiraNúcleo de Estudo da doença de Chagas (NEDoC), Hospital das Clínicas, Federal University of Goiás, Goiânia, Brazil

Search for other papers by Dayse Elisabeth Campos de Oliveira in
Current site
Google Scholar
PubMed
Close
,
Suelene Brito do Nascimento TavaresNúcleo de Estudo da doença de Chagas (NEDoC), Hospital das Clínicas, Federal University of Goiás, Goiânia, Brazil

Search for other papers by Suelene Brito do Nascimento Tavares in
Current site
Google Scholar
PubMed
Close
,
Enio Chaves de OliveiraNúcleo de Estudo da doença de Chagas (NEDoC), Hospital das Clínicas, Federal University of Goiás, Goiânia, Brazil

Search for other papers by Enio Chaves de Oliveira in
Current site
Google Scholar
PubMed
Close
, and
Alejandro O. LuquettiNúcleo de Estudo da doença de Chagas (NEDoC), Hospital das Clínicas, Federal University of Goiás, Goiânia, Brazil

Search for other papers by Alejandro O. Luquetti in
Current site
Google Scholar
PubMed
Close
Restricted access

ABSTRACT.

This study evaluated four biomarkers of inflammation or fibrosis as progression indicators for heart disease in patients with Chagas disease. We compared values of these markers at the time of the first sample collection of blood (first time point) and at the time of the last collection of blood (second time point) for 103 individuals positive for Trypanosoma cruzi antibodies. They were split into two clinical groups: 52 individuals with the indeterminate form of the disease at the first time point and 51 controls that already had either cardiac involvement (N = 25) or megaviscera (megaesophagus and/or megacolon; N = 26) at that time. All individuals had an electrocardiogram performed both at the first and second time point (mean time between time points: 11 years). All samples were blind tested for galectin-3, brain natriuretic peptide (NT-proBNP), lysyl oxidase-like protein 2 (LOXL2), and troponin. Differences in concentrations between samples were analyzed using the months between samples as the covariate. This analysis showed that values for all markers, except troponin biomarker had a significative increase at the second time point for the 91 patients without progression. A similar result was obtained for NT-proBNP and LOXL2 with sera from 12 patients that progressed with cardiac disease. The single marker that showed a significative difference between groups (P = 0.01) was galectin-3. We concluded that galectin-3 was the only marker with a prognostic value in relation to the progression or worsening of heart disease in patients with Chagas disease.

    • Supplemental Materials (PDF 334 KB)

Author Notes

Address correspondence to Alejandro O. Luquetti, Núcleo de Estudo da doença de Chagas (NEDoC), Hospital das Clínicas, 1a. Avenida s/n, Setor Universitario, Federal University of Goiás, Goiânia, CEP: 74605-020, Brazil. E-mail: aluquetti@gmail.com

Disclosure: All authors participate actively in the study. Selection and follow-up of patients was done by Dr. D. E. Campos Oliveira and Dr. E. C. Oliveira, serology by S.B.N. Tavares and A. O. Luquetti, and writing by E. C. Oliveira and A. O. Luquetti. The authors declare that they have no conflicts of interest concerning this article. An initial amount of R$20,500,00 (equivalent at the time to 3,000.00 US$) was received from Biomerieux for expenses with samples.

Authors’ addresses: Dayse Elisabeth Campos de Oliveira, Suelene Brito do Nascimento Tavares, Enio Chaves de Oliveira, and Alejandro O. Luquetti, Núcleo de Estudo da doença de Chagas (NEDoC), Hospital das Clínicas, Federal University of Goiás, Goiânia, Brazil, E-mails: daysecampos2@gmail.com, suelenetavares@gmail.com, eco1.br@gmail.com, and aluquetti@gmail.com.

Save